Skip to main content
. Author manuscript; available in PMC: 2022 Sep 1.
Published in final edited form as: Blood Rev. 2021 Mar 16;49:100825. doi: 10.1016/j.blre.2021.100825

Fig. 3.

Fig. 3.

Only a small subset of patients with newly diagnosed CML will be able to achieve treatment free remission. Among 100 patients with newly diagnosed CML about 10 percent will have accelerated or blast phase at diagnosis and are not eligible for a trial of treatment free remission per current guidelines. Of the 90% who have chronic phase CML, two thirds will achieve sustained DMR. Half of the patients who qualify for a TKI discontinuation trial will experience recurrence necessitating reintroduction of TKIs.